| Description |
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell Apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1].
|
| Related Catalog |
|
| In Vitro |
Tigatuzumab is sensitive to MIA PaCa-2 cells and BxPC-3 cells with IC50 values of 2.95 and 8.21 μg/mL, respectively[1]. Tigatuzumab (3-8 μg/mL; 5 h) induces apoptosis of cancer cells[1]. Apoptosis Analysis[1] Cell Line: MIA PaCa-2 and BxPC-3 cell lines Concentration: 3 and 8 μg/mL Incubation Time: 5 hours Result: Induced cell apoptosis, and the methionine restriction increased the caspase activation and apoptosis in pancreatic cancer cells.
|
| In Vivo |
Tigatuzumab (3 mg/kg; i.v. weekly for 4 weeks) effectively represses the tumor growth in human pancreatic cancer MIA PaCa-2-RFP orthotopic mouse model[1]. Animal Model: Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection[1] Dosage: 3 mg/kg Administration: Intravenous injection; 3 mg/kg weekly for 4 weeks Result: Reduced the tumor volume and decreased the density of viable cancer cells in tumors.
|
| References |
[1]. Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184.
|
